Polyelectrolyte nanocomplex formation of heparin-photosensitizer conjugate with polymeric scavenger for photodynamic therapy

Li, Li; Cho, Hanna; Kim, Sung-Won; Kang, Han Chang; Huh, Kang Moo

doi:10.1016/j.carbpol.2014.12.035

Cited by 6 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second-generation PSs have a variety of functional groups including carboxyl, hydroxyl and amine groups in addition to their basic porphyrin structure, allowing hydrophobic modifications via chemical or physical approaches to form amphiphilic PS derivatives. The PS derivatives synthesized to be amphiphilic can form NPs with various nanostructures such as micelles [ 89 , 95 , 96 , 97 , 98 ], PS-drug conjugates [ 82 , 86 , 92 , 99 , 100 ], polymersomes [ 101 ], and nanogels [ 84 , 102 ] through self-assembly. According to the nanostructure, nanoparticles can be generally categorized into three types: 1) NPs with mixed hydrophilic and hydrophobic domains, 2) NPs with a core-shell structure, and 3) NPs with a double-layered capsule structure ( Figure 2 ).…”

Section: Nanotechnology For Enhanced Photodynamic Therapymentioning

confidence: 99%

“…According to the nanostructure, nanoparticles can be generally categorized into three types: 1) NPs with mixed hydrophilic and hydrophobic domains, 2) NPs with a core-shell structure, and 3) NPs with a double-layered capsule structure ( Figure 2 ). In this respect, natural polysaccharides such as hyaluronic acid (HA) [ 102 , 103 , 104 , 105 ], chitosan [ 102 , 106 , 107 , 108 ], chitin, heparin [ 95 , 99 , 100 ], and fucoidan [ 84 ] have been utilized as potential photosensitizer carriers due to their biocompatibility and biodegradability. In addition, not only polymers but also hydrophobic small molecule anticancer drugs (such as doxorubicin [ 96 ], docetaxel [ 97 , 107 , 109 , 110 ], paclitaxel [ 85 , 93 , 103 , 111 , 112 ], camptothecin, and quercetin [ 113 , 114 ]) can be grafted onto PS.…”

Section: Nanotechnology For Enhanced Photodynamic Therapymentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors

Kim

Lee

2022

Biomedicines

View full text Add to dashboard Cite

The current treatment for malignant brain tumors includes surgical resection, radiotherapy, and chemotherapy. Nevertheless, the survival rate for patients with glioblastoma multiforme (GBM) with a high grade of malignancy is less than one year. From a clinical point of view, effective treatment of GBM is limited by several challenges. First, the anatomical complexity of the brain influences the extent of resection because a fine balance must be struck between maximal removal of malignant tissue and minimal surgical risk. Second, the central nervous system has a distinct microenvironment that is protected by the blood–brain barrier, restricting systemically delivered drugs from accessing the brain. Additionally, GBM is characterized by high intra-tumor and inter-tumor heterogeneity at cellular and histological levels. This peculiarity of GBM-constituent tissues induces different responses to therapeutic agents, leading to failure of targeted therapies. Unlike surgical resection and radiotherapy, photodynamic therapy (PDT) can treat micro-invasive areas while protecting sensitive brain regions. PDT involves photoactivation of photosensitizers (PSs) that are selectively incorporated into tumor cells. Photo-irradiation activates the PS by transfer of energy, resulting in production of reactive oxygen species to induce cell death. Clinical outcomes of PDT-treated GBM can be advanced in terms of nanomedicine. This review discusses clinical PDT applications of nanomedicine for the treatment of GBM.

show abstract

Section: Nanotechnology For Enhanced Photodynamic Therapymentioning

confidence: 99%

Section: Nanotechnology For Enhanced Photodynamic Therapymentioning

confidence: 99%

Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors

Kim

Lee

2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…An original way of preventing ROS production before reaching the target site is the use of a scavenger. In the work from Li et al [103], a PIC is formed between a negatively charged heparine modified with pheophorbide a and a positively charged polyethyleneimine coupled to β-carotene. After disassembly of the nanoparticles, the mean distance between pheophorbide a and β-carotene increases thus activating PDT.…”

Section: Covalent Conjugation Of Photosensitizersmentioning

confidence: 99%

“…This approach was first described for PDT by Kataoka et al in 2005 [47] and has been examined from time to time since then. Recent examples [46,103] described the formation of PICs based on polylysine/tetrasulfonate phthalocyanine or heparin/polyethylene imine interaction. The approach proposed by Huh et al is original since the polyelectrolyte complex is formed by association of a pheophorbide-modified heparin to polyethylene imine-β-carotene, the carotene moiety acting as a ROS scavenger as long as the PIC is formed [103].…”

Section: Ps/vector Affinity and Loadingmentioning

confidence: 99%

“…Recent examples [46,103] described the formation of PICs based on polylysine/tetrasulfonate phthalocyanine or heparin/polyethylene imine interaction. The approach proposed by Huh et al is original since the polyelectrolyte complex is formed by association of a pheophorbide-modified heparin to polyethylene imine-β-carotene, the carotene moiety acting as a ROS scavenger as long as the PIC is formed [103]. The principle is that, once internalized, heparin will be degraded enzymatically and the PIC thus dissociates, enabling the production of ROS upon irradiation.…”

Section: Ps/vector Affinity and Loadingmentioning

confidence: 99%

See 1 more Smart Citation

Rational design of block copolymer self-assemblies in photodynamic therapy

Demazeau¹,

Gibot²,

Mingotaud³

et al. 2020

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

Photodynamic therapy is a technique already used in ophthalmology or oncology. It is based on the local production of reactive oxygen species through an energy transfer from an excited photosensitizer to oxygen present in the biological tissue. This review first presents an update, mainly covering the last five years, regarding the block copolymers used as nanovectors for the delivery of the photosensitizer. In particular, we describe the chemical nature and structure of the block copolymers showing a very large range of existing systems, spanning from natural polymers such as proteins or polysaccharides to synthetic ones such as polyesters or polyacrylates. A second part focuses on important parameters for their design and the improvement of their efficiency. Finally, particular attention has been paid to the question of nanocarrier internalization and interaction with membranes (both biomimetic and cellular), and the importance of intracellular targeting has been addressed.

show abstract

Diketopyrrolopyrrole Derivatives Grafting Hyaluronic Acid for Targeted Photodynamic Therapy

Cai

Tang

et al. 2016

ChemistrySelect

View full text Add to dashboard Cite

Photodynamic therapy (PDT) can effectively avoid the damages on the normal tissues and organs compared to the traditional cancer treatment methods because of its non‐invasive property for the body and high selectivity to tumor site upon light irradiation. Rational design of photosensitizers (PSs) with specific targeting towards tumors and on‐site activation is strongly desirable for precise cancer photodynamic therapy. Herein, a novel hydrophilic tumor‐targeting photosensitizer (DTDPP‐HA) is synthesized by covalently coupling 2,5‐bis‐(6‐bromo‐hexyl)‐3,6‐di‐thiophen‐2‐yl‐2,5‐dihydro‐pyrrolo[3,4‐c]pyrrole‐1,4‐dione (DTDPP) with hyaluronic acid (HA), which presents high singlet oxygen generation and specific targeting to the CD44 receptor overexpressed cancer cells, as well as low dark toxicity and high phototoxicity. More important, both vitro and vivo experiments reveal that DTDPP‐HA can effectively suppress tumor growth. Therefore, the DTDPP‐HA would be a potential and promising theranostic agent for PDT.

show abstract

Polyelectrolyte nanocomplex formation of heparin-photosensitizer conjugate with polymeric scavenger for photodynamic therapy

Cited by 6 publications

References 30 publications

Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors

Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors

Rational design of block copolymer self-assemblies in photodynamic therapy

Diketopyrrolopyrrole Derivatives Grafting Hyaluronic Acid for Targeted Photodynamic Therapy

Contact Info

Product

Resources

About